Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C

Gastroenterology

Volumn 140, Issue 7, 2011, Pages 1961-1969

  Freedman, Neal D ^a   Curto, Teresa M ^b   Lindsay, Karen L ^c   Wright, Elizabeth C ^d   Sinha, Rashmi ^a   Everhart, James E ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Caffeine; Diet; Liver Fibrosis; Risk Factor

Indexed keywords

ALCOHOL; INTERLEUKIN 28; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC DISEASE; CHRONIC HEPATITIS; COFFEE; DRINKING; DRUG DOSE REDUCTION; ETHNICITY; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; TREATMENT RESPONSE; VIRUS DETECTION;

EID: 79958141959     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.02.061     Document Type: Article

References (46)

1. S.L. Chen, and T.R. Morgan The natural history of hepatitis C virus (HCV) infection Int J Med Sci 3 2006 47 52
2. D. Lavanchy The global burden of hepatitis C Liver Int 29 Suppl 1 2009 74 81
3. M.W. Fried, M.L. Shiffman, and K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
4. M.P. Manns, J.G. McHutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
5. A. Kau, J. Vermehren, and C. Sarrazin Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 2008 634 651
6. C. Howell, L. Jeffers, and J.H. Hoofnagle Hepatitis C in African Americans: summary of a workshop Gastroenterology 119 2000 1385 1396
7. D.L. Thomas, and L.B. Seeff Natural history of hepatitis C Clin Liver Dis 9 2005 383 398 vi (Pubitemid 40968202)
8. M.L. Shiffman, A.M. Di Bisceglie, and K.L. Lindsay Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023 (Pubitemid 38451173)
9. S.A. Harrison Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment Clin Gastroenterol Hepatol 6 2008 864 876
10. M. Romero-Gomez, M.V. Del, and R.J. Andrade Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641 (Pubitemid 40585366)
11. V. Suppiah, M. Moldovan, and G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
12. A. Rauch, Z. Kutalik, and P. Descombes Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345
13. Y. Tanaka, N. Nishida, and M. Sugiyama Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
14. D. Ge, J. Fellay, and A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
15. D.L. Thomas, C.L. Thio, and M.P. Martin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
16. G.L. Davis, J.B. Wong, and J.G. McHutchison Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652 (Pubitemid 37052151)
17. J.G. McHutchison, M. Manns, and K. Patel Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
18. M.L. Shiffman, M.G. Ghany, and T.R. Morgan Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C Gastroenterology 132 2007 103 112 (Pubitemid 46127673)
19. E. Arnesen, N.E. Huseby, and T. Brenn The Tromso Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population Scand J Clin Lab Invest 46 1986 63 70 (Pubitemid 16105277)
20. E. Casiglia, P. Spolaore, and G. Ginocchio Unexpected effects of coffee consumption on liver enzymes Eur J Epidemiol 9 1993 293 297 (Pubitemid 23238056)
21. S. Honjo, S. Kono, and M.P. Coleman Coffee consumption and serum aminotransferases in middle-aged Japanese men J Clin Epidemiol 54 2001 823 829 (Pubitemid 32722187)
22. A.L. Klatsky, C. Morton, and N. Udaltsova Coffee, cirrhosis, and transaminase enzymes Arch Intern Med 166 2006 1190 1195 (Pubitemid 43877627)
23. C.E. Ruhl, and J.E. Everhart Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States Gastroenterology 128 2005 24 32 (Pubitemid 40039955)
24. K. Tanaka, S. Tokunaga, and S. Kono Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers Int J Epidemiol 27 1998 438 443 (Pubitemid 28336971)
25. N.D. Freedman, J.E. Everhart, and K.L. Lindsay Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C Hepatology 50 2009 1360 1369
26. S.C. Larsson, and A. Wolk Coffee consumption and risk of liver cancer: a meta-analysis Gastroenterology 132 2007 1740 1745 (Pubitemid 46677953)
27. F. Bravi, C. Bosetti, and A. Tavani Coffee drinking and hepatocellular carcinoma risk: a meta-analysis Hepatology 46 2007 430 435 (Pubitemid 47344778)
28. T. Purnak, and E. Ozaslan Coffee intake and chronic hepatitis C Hepatology 50 2009 1673
29. A.M. Di Bisceglie, M.L. Shiffman, and G.T. Everson Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
30. W.M. Lee, J.L. Dienstag, and K.L. Lindsay Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders Control Clin Trials 25 2004 472 492 (Pubitemid 39299157)
31. G. Block, M. Woods, and A. Potosky Validation of a self-administered diet history questionnaire using multiple diet records J Clin Epidemiol 43 1990 1327 1335
32. G. Block, F.E. Thompson, and A.M. Hartman Comparison of two dietary questionnaires validated against multiple dietary records collected during a 1-year period J Am Diet Assoc 92 1992 686 693
33. C. Morishima, M. Chung, and K.W. Ng Strengths and limitations of commercial tests for hepatitis C virus RNA quantification J Clin Microbiol 42 2004 421 425 (Pubitemid 38082762)
34. J.E. Ware Jr, and C.D. Sherbourne The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection Med Care 30 1992 473 483
35. R.B. D'Agostino Jr Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281 (Pubitemid 28466823)
36. M. Honda, A. Sakai, and T. Yamashita Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2010 499 509
37. T.J. Urban, A.J. Thompson, and S.S. Bradrick IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C Hepatology 52 2010 1888 1896
38. T.R. O'Brien Interferon-alfa, interferon-lambda and hepatitis C Nat Genet 41 2009 1048 1050
39. T. Shen, Y.C. Park, and S.H. Kim Nuclear factor-kappaB/signal transducers and activators of transcription-1-mediated inflammatory responses in lipopolysaccharide-activated macrophages are a major inhibitory target of kahweol, a coffee diterpene Biol Pharm Bull 33 2010 1159 1164
40. S.A. Harrison, L. Rossaro, and K.Q. Hu Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy Hepatology 52 2010 864 874
41. J.H. Li, X.Q. Lao, and H.L. Tillmann Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection Hepatology 51 2010 1904 1911
42. D. Ramcharran, A.S. Wahed, and H.S. Conjeevaram Associations between serum lipids and hepatitis C antiviral treatment efficacy Hepatology 52 2010 854 863
43. J.A. Pineda, A. Caruz, and A. Rivero Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus Clin Infect Dis 51 2010 788 795
44. S.H. Jee, J. He, and L.J. Appel Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials Am J Epidemiol 153 2001 353 362 (Pubitemid 32144561)
45. R. Huxley, C.M. Lee, and F. Barzi Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis Arch Intern Med 169 2009 2053 2063
46. R.M. van Dam, and F.B. Hu Coffee consumption and risk of type 2 diabetes: a systematic review JAMA 294 2005 97 104 (Pubitemid 41002844)